Effect of urgent treatment for transient ischaemic attack and minor stroke on disability and hospital costs (EXPRESS study): a prospective population-based sequential comparison

被引:147
作者
Luengo-Fernandez, Ramon [2 ]
Gray, Alastair M. [2 ]
Rothwell, Peter M. [1 ]
机构
[1] John Radcliffe Hosp, Stroke Prevent Res Unit, Univ Dept Clin Neurol, Oxford OX3 9DU, England
[2] Univ Oxford, Dept Publ Hlth, Hlth Econ Res Ctr, Oxford, England
基金
英国医学研究理事会;
关键词
VASCULAR EVENTS; RISK; INDIVIDUALS; TRIAL;
D O I
10.1016/S1474-4422(09)70019-5
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Evidence is available on the effectiveness and costs of treatments to reduce stroke risk in long-term secondary prevention. However, there are few data on the costs and outcomes of urgent assessment and treatment after the onset of transient ischaemic attack (TIA) or minor stroke. The Early use of eXisting PREventive Strategies for Stroke (EXPRESS) study showed that urgent assessment and treatment reduced the 90-day risk of recurrent stroke by about 80%. We now report the effect of the EXPRESS intervention on admissions to hospital, costs, and disabitity. Methods EXPRESS was a prospective population-based before (phase 1: April 1, 2002, to Sept 30, 2004) versus after (phase 2: Oct 1, 2004, to March 31, 2007) study of the effect of early assessment and treatment of TIA or minor stroke on the risk of early recurrent stroke. This report assesses the effect of the introduction of the phase 2 dinic on admissions to hospital within 90 days, hospital bed-days, hospital costs, and 6-month new disability (progression from no disability before event [modified Rankin scale score :<= 2 points] to disability at 6 months [modified Rankin scale score >2 points]) or death, compared with the phase 1 clinic. To assess the main predictors of these outcomes, multivariate regression analyses were done. Findings The 90-day risk of fatal or disabling stroke was reduced in phase 2 (1 of 281 vs 16 of 310; p=0.0005). Hospital admissions for recurrent stroke were also lower in phase 2 than in phase 1 (5 vs 25; p=0.001), which reduced the overall number of hospital bed-days compared with phase 1 (672 vs 1957 days; p=0.017). Hospital bed-days for admissions to hospital due to vascular causes were also lower in phase 2 (427 vs 1365 days; p=0.016), which generated savings of (sic)624 per patient referred to the phase 2 clinic (p=0.028). Results from the multivariate analyses showed that assessment in phase 2 was an independent predictor of reduced disability, days in hospital, and costs. Interpretation Urgent assessment and treatment of patients with TIA or minor stroke who were referred to a specialist outpatient clinic reduced subsequent hospital bed-days, acute costs, and 6-month disability.
引用
收藏
页码:235 / 243
页数:9
相关论文
共 30 条
[1]   Home or hospital for stroke rehabilitation? Results of a randomized controlled trial - II: Cost minimization analysis at 6 months [J].
Anderson, C ;
Mhurchu, CN ;
Rubenach, S ;
Clark, M ;
Spencer, C ;
Winsor, A .
STROKE, 2000, 31 (05) :1032-1037
[2]  
[Anonymous], 2008, STROK NAT CLIN GUID
[3]  
Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
[4]  
Briggs A, 1998, J Health Serv Res Policy, V3, P233
[5]   Resource utilization and costs of stroke unit care integrated in a care continuum:: A 1-year controlled, prospective, randomized study in elderly patients -: The Goteborg 70+ stroke study [J].
Claesson, L ;
Gosman-Hedström, G ;
Johannesson, M ;
Fagerberg, B ;
Blomstrand, C .
STROKE, 2000, 31 (11) :2569-2577
[6]   Direct assessment of completeness of ascertainment in a stroke incidence study [J].
Coull, AJ ;
Silver, LE ;
Bull, LM ;
Giles, MF ;
Rothwell, PM .
STROKE, 2004, 35 (09) :2041-2045
[7]  
*DEP HLTH, NHS REF COSTS 2005 0
[8]   Lifetime cost of stroke subtypes in Australia findings from the North East Melbourne Stroke Incidence Study (NEMESIS) [J].
Dewey, HM ;
Thrift, AG ;
Mihalopoulos, C ;
Carter, R ;
Macdonell, RAL ;
McNeil, JJ ;
Donnan, GA .
STROKE, 2003, 34 (10) :2502-2507
[9]   A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) [J].
Gent, M ;
Beaumont, D ;
Blanchard, J ;
Bousser, MG ;
Coffman, J ;
Easton, JD ;
Hampton, JR ;
Harker, LA ;
Janzon, L ;
Kusmierek, JJE ;
Panak, E ;
Roberts, RS ;
Shannon, JS ;
Sicurella, J ;
Tognoni, G ;
Topol, EJ ;
Verstraete, M ;
Warlow, C .
LANCET, 1996, 348 (9038) :1329-1339
[10]   Combining multiple approaches for the secondary prevention of vascular events after stroke - A quantitative modeling study [J].
Hackam, Daniel G. ;
Spence, J. David .
STROKE, 2007, 38 (06) :1881-1885